Difference between revisions of "Benralizumab (Fasenra)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5). ==Diseases for which it is used== *Hypereosinophilic syndrome (HES...") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
||
| Line 14: | Line 14: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | + | ||
[[Category:Anti-IL-5 antibodies]] | [[Category:Anti-IL-5 antibodies]] | ||
Revision as of 19:54, 27 February 2020
General information
Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5).
Diseases for which it is used
History of changes in FDA indication
No approval for hematology/oncology conditions, at this time.
Also known as
- Brand names: Fasenra